A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Latest Information Update: 26 Jul 2022
At a glance
- Drugs CAT 2003 (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Astria Therapeutics; Catabasis Pharmaceuticals
- 02 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 07 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.